Furthermore, liraglutide, as a Glucagon-like peptide-1 (GLP-1) analogue and a Glucagon-like peptide-1 receptor (GLP-1R) agonist, has been widely used as an antidiabetic agent worldwide in the treatment of T2D in recent years [12]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.